Patients with coronary artery disease can potentially improve their recovery with a new drug eluting stent, MiStents SES®, a Micell Technologies product. The North Carolina-based company licensed a PNNL-developed process as a part of their broad technology platform to coat the stents with a thin layer of drug eluting material. This rapidly absorbable coating containing crystalline sirolimus is intended to precisely and consistently provide local drug delivery and limit polymer exposure, thereby potentially reducing the risks associated with other available drug-eluting stents. Micell Technologies announced that the MiStent SES will be commercially available in Europe and other select countries this year. The MiStent SES has received CE marking but is not approved in the U.S. or any other countries. Read more at http://bit.ly/1Adbn5W.
Add a comment...